DJIA 16,950.23 30.64 0.18%
NASDAQ 4,527.77 0.26 0.01%
S&P 500 1,983.60 2.00 0.10%
market minute promo

22.48 -0.09 (-0.40%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

ACAD $22.48 -0.40%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $22.43
Previous Close $22.57
Daily Range $22.26 - $22.65
52-Week Range $15.64 - $32.00
Market Cap $2.2B
P/E Ratio -34.20
Dividend (Yield) $0.00 (0.0%)
Volume 317,566
Average Daily Volume 933,350
Current FY EPS -$0.85





ACADIA Pharmaceuticals, Inc. (ACAD) Description

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. Website:

News & Commentary

Alzheimer's Needs Cures, Not Pyrrhic Victories

As the world's largest Alzheimer's research conference kicks off in Denmark, finding a cure is a long shot at best. Still, there are companies worth watching in this space.

ACADIA Pharmaceuticals' (ACAD) CEO Uli Hacksell on Q2 2014 Results - Earnings Call Transcript

ACADIA Pharmaceuticals (ACAD) Q2 2014 Results - Earnings Call Webcast

Edelman's Perceptive Advisors Buying Amicus Therapeutics Ahead Of Phase III Data Release

ACADIA Pharmaceuticals Announces Stephen Davis As Executive VP, CFO And Chief Business Officer

4 Biotech Stocks Worth A Look Ahead Of FDA Approvals

The Path to FDA Approval Could Launch Seven Biotech Stocks Much Higher

ACAD Makes Bullish Cross Above Critical Moving Average

Friday's ETF Movers: FNX, XBI

Are Investors Wrong About Acadia Pharmaceuticals?

Short-sellers have taken a keen interest in clinical-stage biopharma Acadia Pharmaceuticals lately. Here's why.

See More ACAD News...

ACAD's Top Competitors

ACAD $22.48 (-0.40%)
Current stock: ACAD
GILD $101.34 (0.06%)
Current stock: GILD
CELG $92.75 (1.52%)
Current stock: CELG
AMGN $132.61 (-0.31%)
Current stock: AMGN